Skip to main content

opnurasib

Generic: Opnurasib

opnurasib: 6 clinical trials tracked.

opnurasib evidence translation

What we can confirm

6 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about opnurasib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (6)

KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071Registry updated 2026-10-09·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Number of participants receiving opnurasib as single agent or in combination with other study treatments

Interventionalopen25 enrolledStarted 2026-06Completion 2029-0921 sites · Belgium, Canada, China, Denmark…Novartis Pharmaceuticals

Neoadjuvant Platform Trial in Patients With Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

NCT05714891Registry updated 2026-02-12·Phase 2
Active, not recruiting

Primary endpoint: Identify promising neoadjuvant treatment regimens for NSCLC for later validation in randomized clinical trials, by evaluating major pathological response rates (MPR)

Interventionalopen4 targetStarted 2023-09Completion 2028-038 sites · CanadaCanadian Cancer Trials Group

KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843Registry updated 2026-10-08·Phase 2
Active, not recruiting

Primary endpoint: Overall Response Rate (ORR) as Determined by the Investigator in Cohort A

Interventionalopen95 enrolledStarted 2022-12Completion 2026-1045 sites · Argentina, Austria, Belgium, Brazil…Novartis Pharmaceuticals

KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249Registry updated 2026-06-15·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.

Interventionalopen74 targetStarted 2022-10Completion 2026-0913 sites · Belgium, France, Germany, Italy…Novartis Pharmaceuticals

A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075Registry updated 2026-09-25·Phase 3
Active, not recruiting

Primary endpoint: Progression free survival (PFS)

InterventionalRandomizedopen95 enrolledStarted 2022-06Completion 2026-1050 sites · Argentina, Australia, Canada, China…Novartis Pharmaceuticals

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188Registry updated 2026-03-18·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment

Interventionalopen344 targetStarted 2021-02Completion 2027-0138 sites · Australia, Belgium, Canada, China…Novartis Pharmaceuticals